CAR-T & Cell Therapy in China

CAR-T is a one-off treatment in which a patient's own T cells are collected by leukapheresis, genetically engineered to carry a receptor that recognises a specific protein on cancer cells, expanded outside the body, and infused back after lymphodepleting chemotherapy.

Both products approved in China are autologous — the patient's own cells, not an off-the-shelf product. That single fact drives the timeline: collection, manufacturing, release testing, then infusion. It cannot be compressed by paying more, and it is the part foreign patients most often underestimate.

Two CAR-T products have been approved by China's National Medical Products Administration (NMPA). Both were reviewed under accelerated pathways, and neither approval is a general licence — each is tied to a specific label indication.

CAR-T is not offered at every hospital that treats lymphoma or myeloma. It requires a cellular-therapy programme: apheresis capacity, a cryogenic shipping chain to the manufacturing site, an ICU-backed protocol for cytokine release syndrome, and a neurology pathway for neurological toxicity.

No public list of active programmes exists, and a hospital having a haematology department does not mean it has one. We confirm this hospital by hospital during intake rather than publishing a list we cannot verify.

• •Hospital directory →
• •What our coordination covers →

The approved indications are narrow and defined by the label: relapsed or refractory large B-cell lymphoma after two or more lines of therapy for the CD19 product, and relapsed or refractory multiple myeloma after at least three prior lines for the BCMA product.

Beyond the label, each centre applies its own fitness criteria — organ function, prior cell therapy, active infection, neurological status, and whether bridging therapy is needed while cells are manufactured.

Eligibility is decided by the treating haematologist. Nothing on this page is an assessment of whether a specific patient is eligible.

China does not publish a single national price for CAR-T, and the two approved products are priced differently. Public insurance schemes do not routinely cover CAR-T, and foreign self-pay patients sit outside those schemes in any case.

We do not publish a price band we cannot back with a written quotation. Ask us and we will obtain the current figure from the specific centre in writing before you commit to anything.

Published price band: not published — we obtain it in writing from the specific hospital.

The practical sequence is the same for both products. The rate-limiting step is almost never the hospital's willingness — it is manufacturing slot availability and whether the patient is fit enough to wait for it.

• •Send the diagnosis, pathology report, treatment history and recent imaging and labs.
• •We check, centre by centre, whether an active programme exists and whether it accepts international self-pay patients.
• •The centre reviews the records and gives a preliminary view before any travel is booked.
• •If accepted: apheresis date, manufacturing window (typically several weeks), bridging decision, then infusion and a monitored stay.
• •Interpretation and in-person accompaniment throughout, including discharge instructions and follow-up scheduling.